Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Ann Hepatol ; 18(2): 325-330, 2019.
Article in English | MEDLINE | ID: mdl-31010794

ABSTRACT

INTRODUCTION AND AIM: The MELD score has been established as an efficient and rigorous prioritization system for liver transplant (LT). Our study aimed to evaluate the effectiveness of the MELD score as a system for prioritization for LT, in terms of decreasing the dropout rate in the waiting list and maintaining an adequate survival post-LT in Chile. MATERIALS AND METHODS: We analyzed the Chilean Public Health Institute liver transplant registry of candidates listed from October 15th 2011 to December 31st 2014. We included adult candidates (>15 years old) listed for elective cadaveric LT with a MELD score of 15 or higher. Statistical analysis included survival curves (Kaplan-Meier), log-rank statistics and multivariate logistic regression. RESULTS: 420 candidates were analyzed. Mean age was 53.6±11.8 years, and 244 were men (58%). Causes of LT included: Liver cirrhosis without exceptions (HC) 177 (66.4%); hepatocellular carcinoma (HCC) 111 (26.4%); cirrhosis with non-HCC exceptions 102 (24.3%) and non-cirrhotic candidates 30 (7.2%). LT rate was 43.2%. The dropout rate was 37.6% at 1-year. Even though the LT rate was higher, the annual dropout rate was significantly higher in cirrhotic candidates (without exceptions) compared with cirrhotics with HCC, and non-HCC exceptions plus non-cirrhotic candidates (47.9%; 37.2% and 24.2%, respectively, with p=0.004). Post-LT survival was 84% per year, with no significant differences between the three groups (p=0.95). CONCLUSION: Prioritization for LT using the MELD score system has not decreased the dropout rate in Chile (persistent low donor's rate). Exceptions generate inequities in dropout rate, disadvantaging patients without exceptions.


Subject(s)
Cooperative Behavior , Decision Support Techniques , Health Status Indicators , Healthcare Disparities/organization & administration , Interdisciplinary Communication , Liver Transplantation , Tissue and Organ Procurement/organization & administration , Adolescent , Adult , Aged , Chile , Clinical Decision-Making , Female , Graft Survival , Humans , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Male , Middle Aged , Patient Dropouts , Patient Selection , Registries , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Waiting Lists , Young Adult
2.
Eur J Hum Genet ; 24(2): 208-13, 2016 Feb.
Article in English | MEDLINE | ID: mdl-25920558

ABSTRACT

Niemann-Pick disease type B (NPDB) is a rare, inherited lysosomal storage disorder that occurs due to variants in the sphingomyelin phosphodiesterase 1 (SMPD1) gene and the resultant deficiency of acid sphingomyelinase (ASM) activity. While numerous variants causing NPDB have been described, only a small number have been studied in any detail. Herein, we describe the frequency of the p.(Ala359Asp) variant in the healthy Chilean population, and determine the haplotype background of homozygous patients to establish if this variant originated from a common founder. Genomic DNA samples from 1691 healthy individuals were analyzed for the p.(Ala359Asp) variant. The frequency of p.(Ala359Asp) was found to be 1/105.7, predicting a disease incidence of 1/44 960 in Chile, higher than the incidence estimated by the number of confirmed NPDB cases. We also describe the clinical characteristics of 13 patients homozygous for p.(Ala359Asp) and all of them had moderate to severe NPDB disease. In addition, a conserved haplotype and shared 280 Kb region around the SMPD1 gene was observed in the patients analyzed, indicating that the variant originated from a common ancestor. The haplotype frequency and mitochondrial DNA analysis suggest an Amerindian origin for the variant. To assess the effect of the p.(Ala359Asp) variant, we transfected cells with the ASM-p.(Ala359Asp) cDNA and the activity was only 4.2% compared with the wild-type cDNA, definitively demonstrating the causative effect of the variant on ASM function. Information on common variants such as p.(Ala359Asp) is essential to guide the successful implementation for future therapies and benefit to patients.


Subject(s)
Haplotypes/genetics , Niemann-Pick Disease, Type B/genetics , Sphingomyelin Phosphodiesterase/genetics , Chile/epidemiology , DNA, Mitochondrial/genetics , Female , Founder Effect , Genotype , Humans , Middle Aged , Mutation , Niemann-Pick Disease, Type B/epidemiology , Pedigree , Polymorphism, Single Nucleotide , Sphingomyelin Phosphodiesterase/biosynthesis , Sphingomyelin Phosphodiesterase/chemistry
3.
J Hepatol ; 52(4): 501-7, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20189674

ABSTRACT

BACKGROUND & AIMS: Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the standard of care for adults with chronic hepatitis C but was not approved for the treatment of children at the time of this study. The aim of this study was to evaluate the efficacy and safety of PEG-IFN alfa-2b plus RBV in children. METHODS: Children and adolescents ages 3-17 years were treated with PEG-IFN alfa-2b (60microg/m(2)/week) plus RBV (15mg/kg/day). The duration of therapy was 24 weeks for genotype (G) 2 and G3 patients with low viral load (<600,000IU/ml) and 48 weeks for G1, G4, and G3 with high viral load (>or=600,000IU/ml). The primary end point was sustained virologic response (SVR), defined as undetectable hepatitis C virus (HCV) RNA 24 weeks after completion of therapy. RESULTS: SVR was attained by 70 (65%) children. Genotype was the main predictor of response: G1, 53%; G2/3, 93%; G4, 80%. SVRs were similar in younger and older children. Baseline viral load was the main predictor of response in the G1 cohort. No new safety signals were identified, and adverse events (AEs) were generally mild or moderate in severity. Dose was modified because of AEs in 25% of children; 1 child discontinued because of an AE (thrombocytopenia). No serious AEs related to study drugs were reported. CONCLUSION: Therapy with PEG-IFN alfa-2b plus RBV in children and adolescents with chronic hepatitis C offers favorable efficacy, reduced injection frequency, and an acceptable safety profile.


Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Polyethylene Glycols/administration & dosage , Ribavirin/administration & dosage , Adolescent , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Body Height , Body Weight , Child , Child Development , Child, Preschool , Drug Resistance, Viral/genetics , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Interferon-alpha/pharmacokinetics , Male , Polyethylene Glycols/adverse effects , Polyethylene Glycols/pharmacokinetics , Recombinant Proteins , Ribavirin/adverse effects , Ribavirin/pharmacokinetics , Treatment Outcome , Viral Load/drug effects
4.
Rev Med Chil ; 136(6): 793-804, 2008 Jun.
Article in Spanish | MEDLINE | ID: mdl-18769839

ABSTRACT

Liver transplantation is an excellent therapeutic option for terminal liver disease. During the last decades the results of liver transplantation have improved significantly with a patient survival rate of nearly 90% at one year and 80% at 5 years of follow-up. The main indications for liver transplantation include: end-stage liver disease associated to cirrhosis, acute liver failure, and hepatic tumors (mainly hepatocarcinoma). The absolute contraindications for a transplant are less frequent than in the past, and include: severe co-morbidity (cardiac or pulmonary), sepsis, advanced HIV disease and extra-hepatic malignancy. This document presents a Consensus of the main groups performing liver transplantation in Chile, about its indications and contraindications. It also reviews general aspects of liver transplantation, including the selection and referral of liver transplant candidates, allocation of organs and the evaluation of severity of liver disease.


Subject(s)
Carcinoma, Hepatocellular/surgery , Liver Cirrhosis/surgery , Liver Failure, Acute/surgery , Liver Neoplasms/surgery , Liver Transplantation , Chile , Chronic Disease , Contraindications , Donor Selection , Health Services Accessibility , Humans , Liver Transplantation/mortality , Liver Transplantation/pathology , Patient Selection , Reoperation , Severity of Illness Index , Survival Rate , Waiting Lists
5.
Rev. méd. Chile ; 136(6): 793-804, jun. 2008. ilus, tab
Article in Spanish | LILACS | ID: lil-490768

ABSTRACT

Liver transplantation is an excellent therapeutic option for terminal liver disease. During the last decades the results of liver transplantation have improved significantly with a patient survival rate of nearly 90 percent at one year and 80 percent at 5 years of follow-up. The main indications for liver transplantation include: end-stage liver disease associated to cirrhosis, acute liver failure, and hepatic tumors (mainly hepatocarcinoma). The absolute contraindications for a transplant are less frequent than in the past, and include: severe co-morbidity (cardiac or pulmonary), sepsis, advanced HIV disease and extra-hepatic malignancy. This document presents a Consensus of the main groups performing liver transplantation in Chile, about its indications and contraindications. It also reviews general aspects of liver transplantation, including the selection and referral of liver transplant candidates, allocation of organs and the evaluation of severity of liver disease.


Subject(s)
Humans , Carcinoma, Hepatocellular/surgery , Liver Cirrhosis/surgery , Liver Failure, Acute/surgery , Liver Neoplasms/surgery , Liver Transplantation , Chile , Chronic Disease , Donor Selection , Health Services Accessibility , Liver Transplantation , Liver Transplantation/mortality , Liver Transplantation/pathology , Patient Selection , Reoperation , Severity of Illness Index , Survival Rate , Waiting Lists
6.
Rev. méd. Chile ; 134(12): 1558-1561, dic. 2006. ilus, tab
Article in Spanish | LILACS | ID: lil-441435

ABSTRACT

Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) is an autoinflammatory disorder associated to a mutation of the Tumor Necrosis Factor Receptor 1 (TNFR1) whose clinical presentation consists on recurrent episodes of prolonged fever, abdominal pain, myalgias, migratory cutaneous erythema, conjunctivitis or periorbitary edema. The diagnosis is confirmed by genetic analysis of the TNFR1 gene. Its main complication is amyloidosis and the treatment is based on the use of corticosteroids or anti-TNF antibodies. We report a 17 year-old male and 23 year-old female with the syndrome. Both cases had heterozygous mutations of the TNFR1 gene, C30R in the first case and T50M in the second case.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Familial Mediterranean Fever/genetics , Mutation/genetics , Receptors, Tumor Necrosis Factor, Type I/genetics , Familial Mediterranean Fever/drug therapy , Familial Mediterranean Fever/pathology , Haplotypes/genetics , Syndrome
7.
Rev Med Chil ; 134(12): 1558-61, 2006 Dec.
Article in Spanish | MEDLINE | ID: mdl-17277873

ABSTRACT

Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) is an autoinflammatory disorder associated to a mutation of the Tumor Necrosis Factor Receptor 1 (TNFR1) whose clinical presentation consists on recurrent episodes of prolonged fever, abdominal pain, myalgias, migratory cutaneous erythema, conjunctivitis or periorbitary edema. The diagnosis is confirmed by genetic analysis of the TNFR1 gene. Its main complication is amyloidosis and the treatment is based on the use of corticosteroids or anti-TNF antibodies. We report a 17 year-old male and 23 year-old female with the syndrome. Both cases had heterozygous mutations of the TNFR1 gene, C30R in the first case and T50M in the second case.


Subject(s)
Familial Mediterranean Fever/genetics , Mutation/genetics , Receptors, Tumor Necrosis Factor, Type I/genetics , Adolescent , Adult , Familial Mediterranean Fever/drug therapy , Familial Mediterranean Fever/pathology , Female , Haplotypes/genetics , Humans , Male , Syndrome
8.
Rev Med Chil ; 132(8): 979-84, 2004 Aug.
Article in Spanish | MEDLINE | ID: mdl-15478300

ABSTRACT

BACKGROUND: Celiac patients are at high risk of developing insulin-dependent diabetes mellitus, a condition that has a long pre-diabetic period. During this lapse, anti-islet cell antibodies serve as markers for future disease. This may be related with the duration of the exposure to gluten. AIM: To test the hypothesis that long term adherence to a gluten free diet decreases the frequency of risk markers for insulin dependent diabetes mellitus during adolescence and early adulthood. PATIENTS AND METHODS: 158 celiac patients were classified as: G1, (n=30 patients) studied at the time of diagnosis; G2 (n=97 patients) exposed to gluten as a result of non compliance with the gluten free diet and, G3 (n=31 patients) who had maintained a long term, strict gluten free diet. Isotype IgG anti-islet cell antibodies were detected by indirect immunofluorescence using monkey pancreas, results were reported in Juvenile Diabetes Foundation (JDF) units. RESULTS: Celiac patients exposed to a gluten containing diet had a significantly higher prevalence of anti-islet cell antibodies than those who had been exposed only briefly (p < 0.017). In addition, a significantly higher prevalence of anti-islet cell antibodies was observed in those patients whose exposure to gluten was longer than 5 years than in those whose exposure was shorter (p < 0.02). CONCLUSIONS: Celiac patients long exposed to gluten have a significantly higher prevalence of anti-islet cell antibodies than those exposed for a short period. This fact supports the hypothesis that the development of these antibodies is associated with the length of the exposure to gluten.


Subject(s)
Celiac Disease/immunology , Diabetes Mellitus, Type 1/immunology , Glutens/administration & dosage , Islets of Langerhans/immunology , Adolescent , Adult , Autoantibodies/isolation & purification , Biomarkers/blood , Child , Child, Preschool , Diet , Female , Glutens/adverse effects , Humans , Infant , Infant, Newborn , Male , Middle Aged , Risk Factors , Time Factors
9.
Nutrition ; 20(2): 181-6, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14962683

ABSTRACT

OBJECTIVE: Undernutrition is a frequent complication in patients with cystic fibrosis (CF). Elevated energy requirements have been found to be 4% to 33% higher than in controls in some studies. Whether or not this is caused by a primary defect or energy metabolism is still a matter of controversy. To this end, we assessed energy expenditure, nutrition status, and body composition of clinically stable CF outpatients. METHODS: Fifteen clinically stable CF patients, ages 2 to 15 y, were paired with 15 healthy control children. Measurements consisted of anthropometry and body composition. Plasma tocopherol, retinol, and hair zinc content were measured. Resting energy expenditure was determined by indirect calorimetry. Physical activity and dietary intake were recorded by recall methods. RESULTS: Two children were nutritionally at risk according to the weight/height index, eight were normal, three were overweight, and two were obese. Body composition was similar in both groups. Zinc, tocopherol, and retinol levels were low in three, two, and three patients, respectively. Resting energy expenditures were 4.7 MJ/d (1127 +/- 220 kcal/d) in CF children and 4.63 MJ/d (1108 +/- 191 kcal/d) in control children (P = not significant). Physical activity level was sedentary in 86.6% of CF patients; the rest had a light physical activity pattern. Energy intake represented 141% of the estimated daily energy expenditure. CONCLUSIONS: Non-oxygen-dependent CF children, without acute respiratory infection, had resting energy expenditures comparable to those of matched controls. Total energy expenditure was similar to or slightly lower than that in healthy children. Dietary recommendations for CF patients need to be reassessed.


Subject(s)
Body Composition , Cystic Fibrosis/metabolism , Energy Metabolism/physiology , Nutritional Requirements , Nutritional Status , Adolescent , Anthropometry , Basal Metabolism/physiology , Calorimetry, Indirect , Case-Control Studies , Child , Child, Preschool , Cystic Fibrosis/blood , Cystic Fibrosis/complications , Energy Intake/physiology , Exercise/physiology , Female , Humans , Male , Mental Recall , Micronutrients/analysis , Tocopherols/blood , Vitamin A/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...